SST and diabetes mellitus: In type 2 diabetes mellitus (T2DM), somatostatin lowers glucose concentrations by inhibiting glucagon secretion [9,10] and abnormalities in the GH-IGF-1 axis have been associated with increased cardiovascular risk in T2DM [11-13].